泮托拉唑钠对SAP患者血清中IL-6及CRP水平的影响

目的探讨泮托拉唑钠对重症急性胰腺炎患者治疗前后血清中IL-6及CRP的影响及其二者相关性。方法186例重症急性胰腺炎患者随机分为对照组（93例）和观察组（93例），两组均采用常规治疗，观察组加用泮托拉唑钠，选取同期健康体检正常者86名为正常对照组，采用ELISA检测治疗前后及正常对照组血清中IL_6及CRP的水平变化，并分析患者治疗前后二者相关性。结果186例重症急性胰腺炎患者治疗前血清II，-6及CRP水平均明显高于健康对照组（均P〈0．01），于治疗后4h、ld及2d逐渐下降，但仍高于正常对照组（均P〈0．05），至治疗后7d与正常对照组比较差异无统计学意义（易O．05）。同期观察组与对照组比较，均有统计学意义（均P〈0．05），观察组IL-6及CRP水平低于对照组；IL-6及CRP水平的表达有明显相关性（均P〈0．05）；两组均未发现不良反应。结论IL一6及CRP可作为重症急性胰腺炎治疗效果的指标，来判定预后，加用泮托拉唑钠对重症急性胰腺炎疗效肯定。

Effect of pantoprazole sodium on serum levels of IL-6 and CRP in SAP patients.

Objective To investigate effect of pantoprazole sodium on serum levels of IL-6 and CRP in SAP patients before and after treatment. Methods The 186 patients with severe acute pancreatitis were randomly divided into control group （93 cases） and observation group （93 cases） and both were treated with regular treatment, while pantoprazole sodium was added to the observation group. Another 86 normal persons were taken as normal control group. ELISA was used to detect serum IL-6 and CRP levels and the results were compared. Results The serum IL--6 and CRP levels in the observation group were significantly higher than those in the healthy control group （P〈0.01）, the serum levels were gradually decreased 4h, 1 d and 2 D after treatment, but still higher than that of healthy control group （P〈0.01 ;P〈0.05）and no difference statistical significance was noticed seven day after treatment compared with the healthy control group （P〉0.05）, so did between the observation group and the control group （P〈O.05）. No serious adverse reactions were found in both groups during the same period of treatment. Conclusion IL-6 and CRP levies can be taken as the indicators in treatment of severe acute panereatitis for evaluate the prognosis and the efficacy.